Two Directors at Thermo Fisher Scientific Inc sold 413 shares at between 0.000USD and 541.200USD. The significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
Moody's Ratings (Moody's) upgraded the ratings of AbbVie Inc. ("AbbVie") including the long-term issuer rating to A2 from A3, senior unsecured notes to A2 from A3, and the senior unsecured commercial paper rating to Prime-1 from Prime-2. At the same time, we revised AbbVie's outlook to stable from p...
Coterra Energy Inc. (CTRA - $28.06) and Devon Energy Corp. (DVN - $39.94)News Reports Companies Near Potential Tie-Up to Create $60 Billion US Shale Group. According to the Financial Times, CTRA and DVN are in advanced talks about a combination that would create one of the largest oil and natural g
Chop Continues; Nasdaq 100 Testing Major Resistance We maintain our near-term bullish outlook on the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM), which has remained in place since 4/22/25, aside from one week (11/19/25-11/25/25) when we went to neutral. We will stay near-term bullish as long as crucial support levels of 6824 on SPX, $610 on QQQ, and $245 on IWM continue to hold. We see mild deterioration in market dynamics, which may provide a near-term headwind; still, MAG7 earning...
SkyWater Technology Inc. (SKYT - $31.32) and IonQ, Inc. (IONQ - $47.25)Announces $1.8 Billion Cash & Stock Acquisition; Offer Value $35.00/share ($15 Cash + $20 Stock, Subject to Collar); Expected Close 2/3Q' 2026. IONQ announced on January 26, 2026, that it has entered into a definitive agreem
Amicus Therapeutics Inc. (NASDAQ: FOLD - $14.35) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - $56.77)Filed Preliminary Proxy; Highlights From Background of Merger Agreement. FOLD filed its preliminary proxy with details regarding the background of BMRN's acquisition of FOLD, beginning with FOLD
According to SNY, the 61.2% increase from 2023 was primarily due to patient conversion from Lumizyme (available as Myozyme outside the U.S.), and Nexviazyme sales represented approximately 49% of SNY's total Pompe disease franchise sales by YE24. BMRN sees the early launch phase of PomOp as a uniqu
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.